GlaxoSmithKline got its first taste of synthetically lethal cancer therapies via an acquisition. Now it’s trying for a bigger bite of this emerging drug class through a research alliance with Ideaya Biosciences that spans three of the biotech’s programs, all slated to reach clinical trials in the next three years.
{iframe}https://xconomy.com/san-francisco/2020/06/16/gsk-expands-synthetic-lethality-scope-with-120m-ideaya-bio-alliance/?utm_source=Xconomy&utm_campaign=f528e2663b-NEWSLETTER_all_stories&utm_medium=email&utm_term=0_2aa91c0bc9-f528e2663b-288460969&mc_cid=f528e2663b{/iframe}